Article

PsA: Phase 3 confirms rapid and significant response of secukinumab on synovitis

Key clinical point: Evaluation with power Doppler ultrasound revealed a rapid and significant reduction of synovitis in patients with psoriatic arthritis (PsA) upon treatment with secukinumab.

Major finding : At week 12, the adjusted mean change in the global European League Against Rheumatism (EULAR) and the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) (EULAR-OMERACT) synovitis score was significantly higher in secukinumab vs. placebo group (−9 vs. −6; difference −3; P = .004), with the effect of secukinumab evident as early as week 1 of treatment initiation. The incidence of treatment-emergent adverse events in secukinumab vs. placebo group was 58% vs. 57%.

Study details: Findings are 12-week results from ULTIMATE, a phase 3 study including 166 biologic-naive patients with concomitant PsA and synovitis who failed conventional synthetic disease-modifying antirheumatic drugs. Patients were randomly assigned to receive subcutaneous secukinumab (300 mg or 150 mg) or placebo weekly until week 4, followed by 4-weekly dosing until week 52.

Disclosures: This study was funded by Novartis. Some of the authors reported ties with various sources including Novartis. A Duggan, P Goyanka, and C Gaillez declared being employees of or owning stock in Novartis.

Source: D'Agostino MA et al. Rheumatology. 2021 Sep 16. doi: 10.1093/rheumatology/keab628.

Recommended Reading

European agency recommends two new adalimumab biosimilars
MDedge Dermatology
More severe psoriasis linked to an increased risk of PsA
MDedge Dermatology
Acceptance of biosimilars grows but greater use may hinge on switching, interchangeability studies
MDedge Dermatology
First-in-class TYK inhibitor shows durable effect for psoriasis
MDedge Dermatology
Study of biologics’ impact on psoriasis-to-PsA transition contradicts previous findings
MDedge Dermatology
Adalimumab biosimilar Cyltezo gets interchangeability designation
MDedge Dermatology
Few JAK inhibitor users have diminished immune response to COVID-19 vaccines
MDedge Dermatology
Better COVID-19 outcomes confirmed in TNF inhibitor users
MDedge Dermatology
Disease activity-guided dose optimization of TNF inhibitors safe and effective in PsA
MDedge Dermatology
Psoriasis patients initiating biologics more likely to develop PsA
MDedge Dermatology